ANEMOCYTE
LIVE

Serial Number

79188650

Owner

ANEMOCYTE S.R.L.

Attorney

Brian A. Tollefson

Filing Date

Sep 11, 2015

Add to watchlist:

No watchlists yet
View on USPTO

ANEMOCYTE Trademark

Serial Number: 79188650 • Registration: 5215720

ANEMOCYTE is a trademark filed by ANEMOCYTE S.R.L. on September 11, 2015. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ANEMOCYTE S.R.L. (5 trademarks)

Via R. Lepetit, 34

Entity Type: 16

ARETA INTERNATIONAL S.R.L. (2 trademarks)

Via Roberto Lepetit, 34

Entity Type: 03

Trademark Details

Filing Date

September 11, 2015

Registration Date

June 6, 2017

Published for Opposition

March 21, 2017

Goods & Services

[ Surgical apparatus and instruments for medical, dental and veterinary use; medical devices for the introduction of pharmaceutical preparations in the human body, in particular syringes and catheters; medical equipment, namely, centrifuges or other separation devices for the isolation of cell sub-populations from tissues and biopsies; surgical apparatus and instruments for medical and veterinary purpose; electrical medical instruments for use in electroporation of cells and tissues for gene transfer purposes, both in vivo and ex-vivo; electronic medical instruments for use in imaging for diagnostic purposes or for monitoring of vital signs of patients ]

Pharmaceutical and veterinary preparations, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, products for gene therapy, namely, genetically modified cells, viral vectors, nucleic acids; tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy

Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; Providing medical and scientific research information and data on developments in the medical and veterinary fields; scientific and technological services, namely, scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; consultancy to ensure compliance with quality standards and the design and validation of manufacturing processes in the scientific field and medical technology fields

Filing History

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Jun 6, 2026 REM4
PARTIAL INVALIDATION PROCESSED BY THE IB
Jun 4, 2026 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
May 12, 2026 INPS
INVALIDATION PROCESSED
May 12, 2026 INPC
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Mar 26, 2026 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 28, 2025 INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 30, 2025 INPR
INTERNATIONAL REGISTRATION RENEWED
Jul 3, 2025 RNWL
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Feb 28, 2025 NA71
REGISTERED-SEC.71 ACCEPTED
Feb 28, 2025 71AG
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Nov 15, 2024 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 25, 2024 INPR
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Aug 21, 2024 EROP
POST REGISTRATION ACTION MAILED - SEC.71
Feb 24, 2024 PR71
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 12, 2024 APRE
TEAS SECTION 71 RECEIVED
Jun 5, 2023 ES71
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 24, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 24, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 24, 2022 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Oct 24, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 24, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 24, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 24, 2022 COAR
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 6, 2022 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Apr 9, 2021 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 22, 2018 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 28, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 14, 2017 FICS
FINAL DISPOSITION PROCESSED
Sep 14, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 6, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 6, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 21, 2017 NPUB
PUBLISHED FOR OPPOSITION
Mar 21, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Mar 17, 2017 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 1, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 1, 2017 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 1, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 14, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 1, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 1, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 1, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 1, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 1, 2017 CNEA
EXAMINER'S AMENDMENT ENTERED
Feb 1, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 1, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 1, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 1, 2017 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 8, 2017 GNFN
FINAL REFUSAL E-MAILED
Jan 8, 2017 GNFR
FINAL REFUSAL WRITTEN
Jan 8, 2017 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 22, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 22, 2016 CRFA
ASSIGNED TO LIE
Dec 7, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 16, 2016 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 11, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 11, 2016 REAP
REFUSAL PROCESSED BY IB
Jul 29, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 13, 2016 RFCS
REFUSAL PROCESSED BY MPU
Jul 13, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 12, 2016 RFCR
APPLICATION FILING RECEIPT MAILED
Jul 12, 2016 MAFR
NON-FINAL ACTION WRITTEN
Jul 11, 2016 CNRT
ASSIGNED TO EXAMINER
Jul 8, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 8, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 7, 2016 REPR